At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Open Label Study of MK-7009 Administered Concomitantly With Pegylated Interferon Alfa-2a and Ribavirin to Patients With Chronic Hepatitis C Infection After Participation in Other MK-7009 Clinical Trials
In Brief
A Phase 2 clinical trial evaluating Vaniprevir 600 mg b.i.d., Vaniprevir 300 mg b.i.d., and 2 other interventions for Hepatitis C, Chronic. Completed, enrolled 45 participants.
Detailed Summary
This study will provide vaniprevir 600 mg or 300 mg twice daily in combination with pegylated interferon (peg-IFN) and ribavirin (RBV) to participants with chronic hepatitis C virus (HCV) infection who did not achieve viral eradication while participating in a prior vaniprevir clinical trial (MK-7009-004, NCT00518622; MK-7009-007, NCT00704405; MK-7009-009, NCT00704184; and MK-7009-029, NCT00954993).
Study Details
Timeline
Interventions
Oral capsules containing 150 mg vaniprevir, four in the morning and four in the evening, for 48 weeks
Oral capsules containing 150 mg vaniprevir, two in the morning and two in the evening, for 48 weeks
Prefilled syringe containing 180 µg/0.5 mL peg-IFN, for weekly subcutaneous injection, for 48 weeks
Oral tablets containing 200 mg RBV, 5 or 6 tablets, dosage based on the participant's weight (\<75 kg or ≥75 kg, respectively), for 48 weeks